Ignite Creation Date:
2024-05-06 @ 1:38 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01855971
Status:
COMPLETED
Last Update Posted:
2019-05-10
First Post:
2013-05-09
Brief Title:
Using Epigallocatechin Gallate EGCG and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome TESFX
Sponsor:
Parc de Salut Mar
Organization:
Parc de Salut Mar
Study Overview
Official Title:
Estrogen Receptors Beta ER-B as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X TESXF
Status:
COMPLETED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Fragile X syndrome FXS presents alterations in synaptic plasticity that produce intellectual disability can produce improvement Estrogens targeting Estrogen Receptors beta ER-β can act as neuroprotective agents promoting synaptic plasticity and neurite outgrowth and health benefits derived from flavonoids as the flavonol epigallocatechin gallate EGCG phytoestrogens of natural origin are partially explained by their interaction with membrane ER Selective ER-β flavonoids are thus good candidates for their therapeutic evaluation in intellectual disabilities EGCG also targets central intracellular transduction signals altered in FXS and improves memory recognition in a FXS animal modeladenosine triphosphate ATP-inhibitor of phosphatidylinositol 3-kinase PI3Kand mammalian target of rapamycin mTOR and extracellular signal-regulated kinase ERK12 This study targets the synaptic plasticity alterations that underlie the learning and memory impairment but also the computational disability in FXS The hypothesis is that EGCG can act by favoring the physiological processes involved in cognition
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None